Patent Application
20180110234
The current invention relates to blends of coagulants and/or mixtures thereof with improved cheese making properties.
Enzymatic coagulation of milk by milk-clotting enzymes, such as chymosin and pepsin, is one of the most important processes in the manufacture of cheeses. Enzymatic milk coagulation is a two-phase process: a first phase where a proteolytic enzyme, chymosin or pepsin, attacks K-casein, resulting in a metastable state of the casein micelle structure and a second phase, where the milk subsequently coagulates and forms a coagulum.
Chymosin (EC 3.4.23.4) and pepsin (EC 3.4.23.1), the milk clotting enzymes of the mammalian stomach, are aspartic proteases belonging to a broad class of peptidases.
When produced in the gastric mucosal cells, chymosin and pepsin occur as enzymatically inactive pre-prochymosin and pre-pepsinogen, respectively. When chymosin is excreted, an N-terminal peptide fragment, the pre-fragment (signal peptide) is cleaved off to give prochymosin including a pro-fragment. Prochymosin is a substantially inactive form of the enzyme which, however, becomes activated under acidic conditions to the active chymosin by autocatalytic removal of the pro-fragment. This activation occurs in vivo in the gastric lumen under appropriate pH conditions or in vitro under acidic conditions.
The structural and functional characteristics of bovine, i.e. Bos taurus, pre-prochymosin, prochymosin and chymosin have been studied extensively. The pre-part of the bovine pre-prochymosin molecule comprises 16 aa residues and the pro-part of the corresponding prochymosin has a length of 42 aa residues. The active bovine chymosin comprises 323 aa is a mixture of two forms, A and B, both of which are active.
Chymosin is produced naturally in mammalian species such as bovines, camels, caprines, buffaloes, sheep, pigs, humans, monkeys and rats.
Bovine chymosin has for a number of years been commercially available to the dairy industry.
WO02/36752A2 (Chr. Hansen) describes recombinant production of camel chymosin.
WO2013/174840A1 (Chr. Hansen) describes mutants/variants of bovine and camel chymosin.
WO2013/164479A2 (DSM) describes mutants of bovine chymosin.
The references listed immediately below may in the present context be seen as references describing mutants of chymosin:
The prior art references mentioned above focus on the molecular structure and its impact on the specificity or performance of the chymosins.
None of the references disclose the combined effects of different chymosins with different properties and from different origins.
The inventors of present invention have discovered that specific coagulants and/or mixtures thereof may be applied in controlling the bacterial acidification rate and acidification end-point during cheese formation.
Furthermore, the inventors have found that present invention allow a feasible control of the structure development of the soft cheese during ripening and storage by providing specific blends of chymosins.
As discussed in working Examples herein the present inventors have also identified a number of coagulant blends showing commercially attractive traits such as e.g. accelerated curd firmness development that exceed the expected performance.
Based on a comparative analysis of the coagulant blends, the present inventors identified a number of blends that are herein important in the sense that by making a blend one may get an improved and superior coagulant performance.
All definitions of herein relevant terms are in accordance of what would be understood by the skilled person in relation to the herein relevant technical context.
The term “coagulant” relates to an enzyme used to coagulate milk in a cheese making process. For the sake of completeness, chymosin is to be considered as a coagulant.
The term “high C/P coagulant” or “a high C/P ratio coagulant” relates to a coagulant, such as e.g. a chymosin having a C/P>4.5 such as e.g. C/P>5, such as e.g. C/P>6, such as e.g. C/P>7 or a C/P between 6 and 12. Commercially available examples of a high C/P coagulants comprise ChyMax M or ChyMax M1000 (Chr. Hansen A/S) and MaxirenXDS (DSM).
The term “low C/P coagulant” or “low C/P ratio coagulant” relates to a coagulant such as e.g. a chymosin having a C/P<4.5, such as e.g. a C/P<4, such as e.g. a C/P<3, such as e.g. a C/P<2, such as e.g. a C/P<1.5, such as e.g. a C/P<1, such as e.g. a C/P<0.5 or C/P<0.1. Commercially available examples of low C/P coagulants comprise Hannilase L®, Hannilase XP®, Thermolase® and Naturen® all available from Chr. Hansen A/S.
The term “coagulant blend” relates to blends of enzymes used to coagulate milk, e.g. in a cheese making process.
The term “chymosin” relates to an enzyme of the EC 3.4.23.4 class. Chymosin has a high specificity and it clots milk by cleavage of a single 105-Ser-Phe-I-Met-Ala-108 bond in kappa-chain of casein. An alternative name used in the art is rennin.
The term “chymosin activity” relates to chymosin activity of a chymosin enzyme as understood by the skilled person in the present context. The skilled person knows how to determine herein relevant chymosin activity.
In working Example 2 herein is provided an Example of a standard method to determine specific chymosin activity alternatively termed clotting activity or milk clotting activity. As an example the clotting activity may be determined using the REMCAT method, which is the standard method developed by the International Dairy Federation (IDF method).
The term “isolated variant” means a variant that is modified by the hand of man.
The term “mature polypeptide” means a peptide in its final form following translation and any post-translational modifications, such as N terminal processing, C terminal truncation, glycosylation, phosphorylation, etc. In the present context may a herein relevant mature chymosin polypeptide be seen as the active chymosin polypeptide sequence i.e. without the pre-part and/or pro-part sequences.
The term “parent” or “parent polypeptide having chymosin activity” means a polypeptide to which an alteration is made to produce the enzyme variants of the present invention. The parent may be a naturally occurring (wild-type) polypeptide or a variant thereof.
The term “Sequence Identity” relates to the relatedness between two amino acid sequences or between two nucleotide sequences and may calculated according to the methods available to the person skilled in the art.
The term “variant” means a peptide having chymosin activity comprising an alteration, i.e., a substitution, insertion, and/or deletion, at one or more (several) positions. A substitution means a replacement of an amino acid occupying a position with a different amino acid; a deletion means removal of an amino acid occupying a position; and an insertion means adding 1-3 amino acids adjacent to an amino acid occupying a position.
The term “wild-type” chymosin peptide means a chymosin expressed by a naturally occurring organism, such as e.g. a mammalian (e.g. camel or bovine) found in nature.
The term “coagulants with different origins” relates to coagulants derived from different organisms or alternatively by means of genetic modification. Hence a bovine wildtype chymosin and a genetically modified bovine chymosin are in the context of present invention to be considered as coagulants with different origins.
In relation to the chymosin sequences shown in
As understood by the skilled person in the present context—herein relevant sequence identity percentages of mature polypeptide sequences of e.g. sheep, C._bactrianus, camel, pig or rat chymosin with the mature polypeptide of SEQ ID NO: 1 (bovine chymosin—i.e. amino acid positions 59 to 381 of SEQ ID NO: 1) are relatively similar to above mentioned sequence identity percentages.
As exemplified in detail herein, the present invention relates to compositions comprising two or more different coagulants.
In a related aspect, the present invention relates to compositions for clotting milk, the composition comprising a blend of two or more coagulants having different origins.
In a related aspect, the present invention relates to a composition as disclosed herein, wherein the two or more coagulants have different C/P ratios and/or clotting activities, such as e.g. at least a three-fold difference.
In a related aspect, milk clotting activity is determined from the time needed for a visible flocculation of a standard milk substrate prepared from a low-heat, low fat milk powder with a calcium chloride solution of 0.5 g per liter (pH 6.5). The clotting time of a rennet sample is compared to that of a reference standard having known milk-clotting activity and having the same enzyme composition by IDF Standard 110B as the sample. Samples and reference standards are measured under identical chemical and physical conditions. Variant samples are adjusted to approximately 3 IMCU/ml using an 84 mM acetic acid pH 5.5 buffer. Hereafter, 200 μl enzyme is added to 10 ml preheated milk (32° C.) in a glass test tube placed in a water bath, capable of maintaining a constant temperature of 32° C.±1° C. under constant stirring.
The total milk-clotting activity (strength) of a rennet is calculated in International Milk-Clotting Units (IMCU) per ml relative to a standard having the same enzyme composition as the sample according to the formula:
Strength in IMCU/ml=Sstandard×Tstandard×Dsample Dstandard×Tsample
Total protein content was determined using the Pierce BCA Protein Assay Kit from Thermo Scientific following the instructions of the providers.
Specific clotting activity (IMCU/mg total protein) was determined by dividing the clotting activity (IMCU/ml) by the total protein content (mg total protein per ml).
In working Example 3 herein is provided an Example of a standard method to determine proteolytical activity.
As an example, general proteolytic activity may be measured using fluoresecently labelled Bodipy-FL casein as a substrate (EnzChek; Molecular Bioprobes, E6638). Casein derivatives heavily labeled with pH-insensitive green-fluorescent Bodipy-FL result in almost complete quenching of the conjugate's fluorescence. Protease catalyzed hydrolysis releases fluorescent Bodipy-FL. This method is very sensitive which is essential for this experiment as high C/P coagulants often have low general proteolytical activity compared to low C/P coagulants.
The assay was conducted in a 0.2 M phosphate buffer adjusted to the desired pH at a final substrate concentration of 0.04 mg/ml. Prior to mixing 1 part of substrate with 1 part of enzyme, both prepared in the phosphate buffer, all enzyme variants where normalized to 50 IMCU/ml (according to example 2). The substrate and enzyme were mixed in a 96-well Nunc Fluoro microtitter plates, sealed and incubated at 32° C. for 60 min. After incubation the sealing was removed and the fluorescence recorded in a fluorimeter.
As known in the art the herein relevant so-called C/P ratio is determined by dividing the specific clotting activity (C)(IMCU/ml) with the proteolytical activity (P)(mU/ml.
As known in the art—a higher C/P ratio implies generally that the loss of protein during e.g. cheese manufacturing due to non-specific protein degradation is reduced, i.e. the yield of cheese is improved, and that the development of bitter taste in the cheese during maturation is reduced.
Another aspect of the invention relates to compositions comprising two or more different chymosins, wherein the compositions entail beneficial properties on the curd firmness and coagulation speed.
On way of measuring this is to use the CHYMOgraph®. The CHYMOgraph® allows for an estimation of the milk flocculation time as well as the curd firmness evolution in cheese production.
The software measures the organization speed of the protein network in the curd. The variation in milk density and curd visco-elasticity is tranformed in user-friendly graphical data, which can be used for the coagulant characterization or to define the optimal curd cut time.
The CHYMOgraph® measures the milk flocculation time, the curd firmness and its evolution and the organisation speed of the protein network.
For preparation of the milk, a container 500 g of milk according to the target of milk composition was prepared and heated to renneting temperature at 38° C. in water bath 1 hour before adding rennet. Before use of milk, pH was controlled and register. An example of a preferred milk composition is:
Fortified milk with 3.8% of protein, high heat treated at 90° C. for 30 s, pH at renneting: 6.18 at 38° C. and 6.28 at (4° C.).
Renneting temperature: 38° C. This milk type corresponds to the milk composition used when producing soft cheese milk type.
Preferred coagulant are prepared as: 3 coagulant solutions are tested: Camel chymosin (ChyMax® M1000), Bovine Chymosin (ChyMax®+) and ChyMaxM soft (a blend of 80% Camel chymosin (ChyMax® M1000) and 20% bovine chymosin (ChyMax® +)). Each coagulant solution may be prepared with a strength of 20 IMCU/mL dilution with warm water. This dilution aims to bring enough coagulant in the milk sample to facilitate its dispersion.
Each coagulant solution may be added to the milk (1 mL for 500 g of milk, so 40 IMCU/1 L). After coagulant addition the sample was mixed 30 seconds by turning. After turning, 10 mL of each coagulant solution was added to the Chymograph.
As known in the art—different natural wildtype chymosin polypeptide sequences obtained from different mammalian species (such as e.g. bovines, camels, sheep, pigs, or rats) are having a relatively high sequence similarity/identity.
In
In the present context a naturally obtained wildtype chymosin (such as bovine chymosin or camel chymosin) as shown in
In a further related aspect, the present invention relates to a composition as disclosed herein, wherein the two or more coagulants form αS1 and/or β-casein at different rates.
In yet a related aspect, the present invention relates to a composition as disclosed herein, wherein the two or more coagulants have different general proteolytic activity, such as e.g. at least a three-fold difference.
Hence in an aspect, the present invention provides compositions as described above, wherein the composition comprises at least one coagulant having a C/P ratio of more than 5 IMCU/mU and at least a second coagulant having a C/P ratio in the range of 0.05 to 1.5 IMCU/mU.
For example, the composition may comprise at least 50 w/w % of one coagulant having a C/P ratio of more than 5 IMCU/mU and at least 15 w/w % of a second coagulant having a C/P ratio in the range of 0.05 to 1.5 IMCU/mU, wherein the w/w % indicates the concentration of one coagulant relative to the total amount of coagulant. In a further aspect, the invention provides a composition comprising at least 70 w/w % of one coagulant having a C/P ratio of more than 5 IMCU/mU and between 15 and 30 w/w % of a second coagulant having a C/P ratio in the range of 0.05 to 1.5 IMCU/mU, wherein the w/w % indicates the concentration of one coagulant relative to the total amount of coagulant.
In yet a related aspect, the present invention relates to a composition as disclosed herein, wherein the composition comprising a blend of two or more coagulants derived from two or more different animal or microbial species or genuses.
In yet a related aspect, the present invention relates to a composition as disclosed herein, wherein the composition comprises a blend of two or more coagulants that are variants of the same parent coagulant.
In yet a related aspect, the present invention relates to a composition as disclosed herein, wherein the two or more different genuses or species is selected from the list consisting of: cow, buffalo, camel, pig, rat, sheep or mucor.
In yet a related aspect, the present invention relates to a composition as disclosed herein, wherein at least one of the two or more different coagulants is derived from a coagulant derived from cow, buffalo, camel, pig, rat, sheep and/or mucor.
In yet a related aspect, the present invention relates to a composition as disclosed herein, wherein the composition comprises milk such as e.g. soya milk, sheep milk, goat milk, buffalo milk, yak milk, lama milk, camel milk or cow milk; and
In yet a related aspect, the present invention relates to a composition as disclosed herein, wherein the composition is a blend of a bovine coagulant and a non-bovine coagulant or is a blend of a camel coagulant and a non-camel coagulant.
In yet a related aspect, the present invention relates to a composition as disclosed herein, wherein the composition comprise from 10-50%, such as e.g. 20% of a non-bovine or a non-camel coagulant, relative to the total amount of coagulant.
In yet a related aspect, the present invention relates to a composition as disclosed herein, wherein the composition comprise a high C/P ratio coagulant and a low C/P ratio coagulant. In yet a related aspect, the present invention relates to a composition as disclosed herein, wherein the composition comprise from 10-50%, such as e.g. 20% of a low C/P ratio coagulant relative to the total amount of coagulant.
In a further embodiment the present invention provides a food or feed composition comprising a blend of two or more coagulants as described above.
The food or feed composition can be a soft-cheese, such as e.g. brie or camembert.
In yet a related aspect, the present invention relates to a composition as disclosed herein, wherein the composition is for making soft-cheese, such as e.g. brie or camembert, optionally, the soft-cheese is a surface ripened soft-cheese.
Further, the invention relates to the use of a composition according as described in any of the aspects herein, in a process for making soft-cheese. The composition as described in the aspects herein, may be added no later than 20 minutes, such as e.g. no later than 15 minutes, such as e.g. no later than 10 minutes, such as e.g. no later than 5 minutes after the addition of one or more starter cultures
If applicable, further manufacturing steps to obtain the milk based product any be added.
For example, the present invention provides a method for making a fermented milk product comprising the following steps:
The method can advantageously be used to make soft-cheese, such as e.g. brie or camembert.
Again, the composition as described in any of the aspects herein may as a related embodiment be added no later than 20 minutes, such as e.g. no later than 15 minutes, such as e.g. no later than 10 minutes, such as e.g. no later than 5 minutes after the addition of one or more starter cultures.
As discussed above—as a reference sequence for determining the amino acid position of a herein relevant chymosin polypeptide of interest (e.g. camel, sheep, bovine etc.) is herein used the public known bovine chymosin sequence disclosed as SEQ ID NO: 1 herein.
By using well-known computer programs as mentioned above it is routine work for the skilled person to determine the amino acid position of a herein relevant chymosin polypeptide of interest (e.g. camel, sheep, bovine etc.) in a corresponding chymosin.
As discussed above—as known in the art, the skilled person may, based on his common general knowledge, routinely produce and purify chymosin and chymosin variants. Said in other words, once the skilled person is in possession of a herein relevant parent polypeptide having chymosin activity of interest (e.g. from bovines, camels, sheep, pigs, or rats) it is routine work for the skilled person to make a variant of such a parent chymosin of interest.
An example of a suitable method to produce and isolate a chymosin (variant or parent) may be by well-known e.g. fungal recombinant expression/production based technology as e.g. described in WO02/36752A2 (Chr. Hansen).
As known in the art—chymosin activity may be determined by the so-called C/P ratio, which is determined by dividing the specific clotting activity (C) with the proteolytical activity (P).
In working Example 2 herein is described a suitable method to determine the specific clotting activity (C) and in working Example 3 herein is described a suitable method to determine proteolytical activity (P).
As discussed above—as a reference sequence for determining the amino acid position of a herein relevant chymosin polypeptide of interest (e.g. camel, sheep, bovine etc.) is herein used the public known bovine chymosin sequence disclosed as SEQ ID NO: 1 herein.
As discussed above—based on e.g. the computer sequence alignment programs discussed herein—it is routine work for the skilled person to determine the herein relevant amino acid position of a herein relevant chymosin polypeptide of interest (e.g. camel, sheep, bovine etc.).
As understood by the skilled person in the present context—a herein relevant parent polypeptide having chymosin activity may already e.g. be a variant of e.g. a corresponding wildtype chymosin. For instance, a camel chymosin variant with e.g. 5-10 alterations (e.g. substitutions) as compared to wildtype camel chymosin polypeptide of SEQ ID NO: 2 will still be a parent polypeptide that has at least 65% sequence identity with the mature polypeptide of SEQ ID NO: 1 (Bovine) as required in e.g. first aspect herein.
Said in other words, a herein relevant isolated chymosin polypeptide variant may comprise alterations (e.g. substitutions) in other position than the positions of e.g. the first aspect herein.
An embodiment relates to an isolated chymosin polypeptide variant, wherein the alteration comprises a substitution, a deletion or an insertion in at least one amino acid position corresponding to any of positions of e.g. the first aspect herein.
It may be preferred that the difference in chymosins exist in at least one alteration of the peptide is a substitution—i.e. a herein relevant coagulant relates to an isolated bovine chymosin polypeptide variant, such as e.g. a variant wherein the alteration is comprising a substitution in at least one amino acid position corresponding to any of positions 51 and/or 221, preferably A51V and K221M in a mature bovine chymosin parent sequence.
Preferably, the parent polypeptide has at least 70% sequence identity with the mature polypeptide of SEQ ID NO: 1 (bovine chymosin), more preferably the parent polypeptide has at least 75% sequence identity with the mature polypeptide of SEQ ID NO: 1 (bovine chymosin).
As an example—a herein suitable relevant parent polypeptide could e.g. be bovine chymosin A—as known in the art bovine chymosin A may only have one amino acid difference as compared to bovine chymosin B of SEQ ID NO: 1 herein.
As discussed above—in working examples herein were made variants using the polypeptide of SEQ ID NO: 1 (Bovine) as parent polypeptide—such variant may herein be termed bovine chymosin variants.
Accordingly, in a preferred embodiment—the parent polypeptide has at least 90% sequence identity with the mature polypeptide of SEQ ID NO: 1 (bovine chymosin), more preferably the parent polypeptide has at least 95% sequence identity with the mature polypeptide of SEQ ID NO: 1 (bovine chymosin) and even more preferably the parent polypeptide has at least 97% sequence identity with the mature polypeptide of SEQ ID NO: 1 (bovine chymosin). It may be preferred that the parent polypeptide is the mature polypeptide of SEQ ID NO: 1 (bovine chymosin).
As understood by the skilled person in the present context—a herein relevant parent polypeptide having chymosin activity may already e.g. be a variant of e.g. a corresponding wildtype chymosin.
As discussed above—an composition comprising two or more different coagulants as described herein may be used according to the art—e.g. to make a milk based product of interest (such as e.g. a cheese product).
As discussed above—an aspect of the invention relates to a method for making a food or feed product comprising adding an effective amount of the coagulant blends as described herein to the food or feed ingredient(s) and carrying our further manufacturing steps to obtain the food or feed product.
Preferably, the food or feed product is a milk based product and wherein the method comprises adding an effective amount of the coagulant blend as described herein to milk and carrying our further manufacturing steps to obtain the milk based product.
The milk may e.g. be soy milk, sheep milk, goat milk, buffalo milk, yak milk, lama milk, camel milk or cow milk.
The milk based product may e.g. be a fermented milk product, a quark or a cheese.
The invention further relates to the following related summarizing aspects:
Aspect 1. A composition for clotting milk, the composition comprising a blend of two or more coagulants with different C/P ratios.
Aspect 2. A composition for clotting milk, the composition comprising a blend of two or more coagulants with different origins, such as e.g. a camel chymosin and a bovine chymosin.
Aspect 3. A composition according to aspect 1 or 2, wherein the two or more coagulants have different general proteolytic activity, such as e.g. at least a three-fold difference.
Aspect 4. A composition according to any of the preceding aspects wherein the composition comprises at least one coagulant having a C/P ratio of more than 5 IMCU/mU and at least a second coagulant having a C/P ratio of 0.05 to 1.5 IMCU/mU.
Aspect 5. A composition according to any of the preceding aspects, wherein the composition comprises at least 50 w/w % of one coagulant having a C/P ratio of more than 5 IMCU/mU and at least 15 w/w % of a second coagulant having a C/P ratio in the range of 0.05 to 1.5 IMCU/mU, wherein the w/w % indicates the concentration of one coagulant relative to the total amount of coagulant.
Aspect 6. A composition according to any of the preceding aspects wherein the composition comprises a blend of two or more coagulants derived from two or more different animal or microbial species or genuses.
Aspect 7. A composition according to any one of the preceding aspects, wherein the composition comprises at least 70 w/w % of one coagulant having a C/P ratio of more than 5 IMCU/mU and between 15 and 30 w/w % of a second coagulant having a C/P ratio in the range of 0.05 to 1.5 IMCU/mU, wherein the w/w % indicates the concentration of one coagulant relative to the total amount of coagulant.
Aspect 8. A composition according to any one of aspects 1 to 7, wherein at least one of the two or more different coagulants is derived from a coagulant derived from cow, buffalo, camel, pig, rat, sheep and/or mucor.
Aspect 9. A composition according to any of the preceding aspects, wherein the composition comprises milk such as e.g. soya milk, sheep milk, goat milk, buffalo milk, yak milk, lama milk, camel milk or cow milk.
Aspect 10. A composition according to aspect 9, wherein the milk is cows milk.
Aspect 11. A composition according to aspect 9 or 10, wherein the milk contain from about 3% to about 5% protein, such as from 3.5% to 4.5% protein, such as 3.8% protein.
Aspect 12. A composition according to any of aspects 9 to 11, wherein the milk comprises from about 1.5% to 5% fat, such as from 2.5% to 4% fat, such as 3.5% fat.
Aspect 13. A composition according to any of aspects 1 to 12, wherein the composition is a blend of a bovine coagulant and a non-bovine coagulant or is a blend of a camel coagulant and a non-camel coagulant, such as e.g. a blend of camel and bovine chymosin.
Aspect 14. Food or feed composition comprising a blend of two or more coagulants according to any of the preceding aspects.
Aspect 15. Food or feed composition according to aspect 14, wherein the composition is soft-cheese, such as e.g. brie or camembert.
Aspect 16. Food or feed composition according to aspect 15, wherein the soft-cheese is a surface ripened soft-cheese.
Aspect 17. Use of a composition according to any one of aspects 1 to 13 in a process for making soft-cheese.
Aspect 18. Use according to aspect 17, wherein the composition according to any of aspects 1 to 13 is added to milk no later than 20 minutes, such as e.g. no later than 15 minutes, such as e.g. no later than 10 minutes, such as e.g. no later than 5 minutes after the addition of one or more starter cultures.
Aspect 19. A method for making a milk-based product comprising adding an effective amount of the composition according to any of aspects 1 to 13 and carrying out further manufacturing steps to obtain the milk based product.
Aspect 20. A method for making a fermented milk product comprising the following steps:
Aspect 21. The method according to aspect 20, wherein the composition according to any of aspects 1 to 13 is added no later than 20 minutes, such as e.g. no later than 15 minutes, such as e.g. no later than 10 minutes after the addition of one or more starter cultures.
Aspect 22. The method according to aspect 20 or 21, wherein the method is used to make soft-cheese, such as e.g. brie or camembert.
Chymosin protein sequences were aligned using the ClustalW algorithm as provided by the EBI (EBI, tools, multiple sequence alignment, CLUSTALW”, http://www.ebi.ac.uk/Tools/msa/clustalw2/) and as described in Larkin M A, Blackshields G, Brown N P, Chenna R, McGettigan P A, McWilliam H, Valentin F, Wallace I M, Wilm A, Lopez R, Thompson J D, Gibson T J, Higgins D G (2007). Bioinformatics 23(21), 2947-2948.
ClustalW2 settings for multiple sequence alignments were Protein weight Matrix=BLOSUM, GAP open=10, GAP EXTENSION=0.05, GAP DISTANCES=8, No End Gaps, ITERATION=none, NUMITER=1, CLUSTERING=NJ
As a reference sequence the bovine chymosin B preprochymosin was used (Genbank accession number P00794 disclosed herein as SEQ ID NO: 1), where the N-terminal Methionin has number 1 (MRCL) and the C-terminal Isoleucin (in the protein sequence . . . LAKAI) has number 381. Variants were aligned against the bovine B pre-pro-chymosin and residues were numbered according to the corresponding bovine chymosin residue.
Milk clotting activity was determined using the REMCAT method, which is the standard method developed by the International Dairy Federation (IDF method) Milk clotting activity is determined from the time needed for a visible flocculation of a standard milk substrate prepared from a low-heat, low fat milk powder with a calcium chloride solution of 0.5 g per liter (pH 6.5). The clotting time of a rennet sample is compared to that of a reference standard having known milk-clotting activity and having the same enzyme composition by IDF Standard 110B as the sample. Samples and reference standards were measured under identical chemical and physical conditions. Variant samples were adjusted to approximately 3 IMCU/ml using an 84 mM acetic acid pH 5.5 buffer. Hereafter, 200 μl enzyme was added to 10 ml preheated milk (32° C.) in a glass test tube placed in a water bath, capable of maintaining a constant temperature of 32° C.±1° C. under constant stirring.
The total milk-clotting activity (strength) of a rennet was calculated in International Milk-Clotting Units (IMCU) per ml relative to a standard having the same enzyme composition as the sample according to the formula:
Total protein content was determined using the Pierce BCA Protein Assay Kit from Thermo Scientific following the instructions of the providers.
Specific clotting activity (IMCU/mg total protein) was determined by dividing the clotting activity (IMCU/ml) by the total protein content (mg total protein per ml).
General proteolytic activity was measured using fluoresecently labelled Bodipy-FL casein as a substrate (EnzChek; Molecular Bioprobes, E6638). Casein derivatives heavily labeled with pH-insensitive green-fluorescent Bodipy-FL result in almost complete quenching of the conjugate's fluorescence. Protease catalyzed hydrolysis releases fluorescent Bodipy-FL. This method is very sensitive which was essential for this experiment as CHYMAX M has the lowest general proteolytical activity of all coagulants known to date.
The assay was conducted in a 0.2 M phosphate buffer adjusted to the desired pH at a final substrate concentration of 0.04 mg/ml. Prior to mixing 1 part of substrate with 1 part of enzyme, both prepared in the phosphate buffer, all enzyme variants where normalized to 50 IMCU/ml (according to example 2). The substrate and enzyme were mixed in a 96-well Nunc Fluoro microtitter plates, sealed and incubated at 32° C. for 60 min. After incubation the sealing was removed and the fluorescence recorded in a fluorimeter.
In soft cheese technology, using a high C/P ratio coagulant such as ChyMax®M has several interests. Some of the more important are: increased shelf life, reduced bitterness, increased fat recovery due to higher firmness at cutting, reduced post-acidification especially in the case of use of fast strains. However, a general modification which can in some case be considered as a default is higher cheese firmness.
In order to keep the interests of High C/P ratio such as ChyMax®M and reduce firmness of the cheese, a blend of ChyMax®M and other coagulants with lower C/P ratio have been defined.
Brie type stabilized soft cheeses have been produced with different coagulant ratios. Cheeses have been analyzed at demolding and during shelf life.
(Values are Average of 5 Vats)
To follow the coagulation behavior, we have used the CHYMOgraph® (patented Chr. Hansen tool). The CHYMOgraph® allows for an estimation of the milk flocculation time as well as the curd firmness evolution in cheese production.
The software measures the organization speed of the protein network in the curd. The variation in milk density and curd visco-elasticity is tranformed in user-friendly graphical data, which can be used for the coagulant characterization or to define the optimal curd cut time.
The CHYMOgraph® measures the milk flocculation time, the curd firmness and its evolution and the organisation speed of the protein network.
A container 500 g of milk according to the target of milk composition was prepared and heated to renneting temperature at 38° C. in water bath 1 hour before adding rennet. Before use of milk, pH was controlled and register.
Fortified milk with 3.8% of protein, high heat treatment: 90° C. for 30 s, pH at renneting: 6.18 at 38° C. and 6.28 at (4° C.).
Renneting temperature: 38° C. This milk type corresponds to the milk composition used when producing soft cheese milk type.
3 coagulant solutions were tested: Camel chymosin (ChyMax® M1000), Bovine Chymosin (ChyMax®+) and ChyMaxM soft (a blend of 80% Camel chymosin (ChyMax® M1000) and 20% bovine chymosin (ChyMax® +)). Each coagulant solution was prepared with a strength of 20 IMCU/mL dilution with warm water. This dilution aims to bring enough coagulant in the milk sample to facilitate its dispersion.
Each coagulant solution was added to the milk (1 mL for 500 g of milk, so 40 IMCU/1 L). After coagulant addition the sample was mixed 30 seconds by turning. After turning, 10 mL of each coagulant solution was added to the Chymograph.
As depicted in
| Number | Date | Country | Kind |
|---|---|---|---|
| 15154513.4 | Feb 2015 | EP | regional |
| Filing Document | Filing Date | Country | Kind |
|---|---|---|---|
| PCT/EP2016/052842 | 2/10/2016 | WO | 00 |
